AZD1390

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

AZD1390 (AZD-1390) 是一种新型有效、选择性、口服、CNS 渗透性 ATM 抑制剂，IC50 为 0.78 nM。

AZD1390 (AZD-1390) is a novel potent, selective, orally available and CNS penetrant ATM inhibitor with IC50 of 0.78 nM, displays >1,000-fold selectivity over closely related (PIKKs) and distant kinases; radiosensitises a panel of glioblastoma multiforme (GBM) cell lines and NCI-H2228 lung cells (IC50=3 nM); demonstrates potential in combination with radiation therapy for the treatment of brain tumors.Brain Cancer,Phase 1 Clinical(In Vivo):Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390.

——

Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390.

AZD 1390 | AZD-1390

Cell Cycle/DNA Damage

ATM/ATR

ATM

Cancer

Brain Cancer

2089288-03-7

477.584

C27H32FN5O2

>98% (HPLC)

DMSO: 20 mg/mL, Need ultrasonic and warming （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(N1C(C)C)N(C)C2=C1C3=CC(C4=CC=C(OCCCN5CCCCC5)N=C4)=C(F)C=C3N=C2

2H-Imidazo[4,5-c]quinolin-2-one,7-fluoro-1,3-dihydro-3-methyl-1-(1-methylethyl)-8-[6-[3-(1-piperidinyl)propoxy]-3-pyridinyl]-

(-20℃)

With Ice Pack

≥ 2 years